Shenzhen Herz Life Science Technology Co., Ltd. 

was founded in March 2020 by Dr. Lisa Cha, a returned scientist from Europe, and is headquartered in Guangming District, Shenzhen. The company has established a fourth-generation new vaccine technology platform with independent intellectual property rights, which is safer and more immunogenic than traditional vaccines, and can be used for the development of endogenous target vaccines. The company has used this technology platform to develop a number of innovative vaccines, including cat sterilization vaccine and feline abdominal vaccine, among which cat sterilization vaccine, as the world's first pet sterilization vaccine, is simultaneously carrying out new veterinary drug registration applications with the Ministry of Agriculture and Rural Affairs of China and the US FDA.

The company has a R&D base of about 4,000 square meters and a pilot production base of 6,000 square meters, and has applied for 37 Chinese and PCT patents, of which 14 have been authorized. Since 2021, it has received multiple rounds of investment from Triwise,Cowincapital, Innovent Biologics, Northern Lights and other institutions, with a financing amount of hundreds of millions of yuan.